高级检索
当前位置: 首页 > 详情页

A multiomics dataset of paired CT image and plasma cell-free DNA end motif for patients with pulmonary nodules

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. [2]Laboratory of Omics Technology and Bioinformatics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, 610041, China. [4]Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Engineering Medicine, Beihang University, Beijing, China. [5]Key Laboratory of Big Data-Based Precision Medicine, Beihang University, Ministry of Industry and Information Technology, Beijing, China. [6]CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China. [7]Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. [8]Tailai Inc., Chengdu, Sichuan, China. [9]Department of Thoracic Surgery, Affiliated Hospital of Zunyi Medical College, Zunyi Medical College, Guizhou, China. [10]Department of Thoracic Surgery, Ningbo No.2 Hospital, Zhejiang, China. [11]Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China. [12]Department of Thoracic Surgery, The First Hospital of Lanzhou University, Gansu, China. [13]Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [14]Department of Radiology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
出处:

摘要:
Diagnosing lung cancer at a curable stage offers the opportunity for a favorable prognosis. The emerging epigenomics analysis on plasma cell-free DNA (cfDNA), including 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) modifications, has acted as a promising approach facilitating the identification of lung cancer. And, integrating 5mC biomarker with chest computed tomography (CT) image features could optimize the diagnosis of lung cancer, exceeding the performance of models built on single feature. However, the clinical applicability of integrated markers might be limited by the potential risk of overfitting due to small sample size. Hence, we prospectively collected peripheral blood sample and the paired chest CT images of 2032 patients with indeterminate pulmonary nodules across 5 centers, and constructed a large-scale, multi-institutional, multiomics database that encompass CT imaging data and plasma cfDNA fragmentomic in 5mC-, 5hmC-enriched regions. To our best knowledge, this dataset is the first radio-epigenomic dataset with the largest sample size, and provides multi-dimensional insights for early diagnosis of lung cancer, facilitating the individuated management for lung cancer.© 2025. The Author(s).

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 综合性期刊
小类 | 2 区 综合性期刊
最新[2025]版:
大类 | 2 区 综合性期刊
小类 | 2 区 综合性期刊
第一作者:
第一作者机构: [1]Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
共同第一作者:
通讯作者:
通讯机构: [2]Laboratory of Omics Technology and Bioinformatics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, 610041, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:57805 今日访问量:0 总访问量:4771 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号